Biotech NeOnc Technologies' share registration declared effective ahead of Nasdaq direct listing
NeOnc Technologies Holdings, a Phase 2 biotech developing intranasal and oral therapies for brain cancer, announced the effectiveness of its registration statement pursuant to a direct listing on the Nasdaq on March 26, 2025. The company registered 2.1 million...read more